van Bever H P, Bridts C H, Moens M M, De Rijck T E, Mertens A V, De Clerck L S, Stevens W J
Department of Immunology, Rheumatology, University Hospital Antwerp, Belgium.
Clin Exp Allergy. 1993 Aug;23(8):661-8. doi: 10.1111/j.1365-2222.1993.tb01792.x.
In the first part of this study the proliferative response of lymphocytes (lymphocyte transformation test) to house dust mite (HDM) stimulation in cultures was studied in normal children (n = 16), asthmatic children who never received hyposensitization (HS) (n = 50) and asthmatic children receiving HS with HDM for at least 6 months (n = 20). The results are expressed as disintegrations per minute (d.p.m.) and as stimulation index (SI = d.p.m. in the presence of the allergen/d.p.m. in the control culture). A positive SI (> 2) was found in 54% of the asthmatic children who never received HS, in 30% of the asthmatics receiving HS and in none of the normal children. Furthermore, between asthmatics with and without HS, the SI was not statistically different, although asthmatics without HS tended to have a higher SI (median value: 2.13 vs 1.38) (P = 0.10). In a second series of experiments the effect of adding interleukin-2 (IL-2) to the lymphocyte cell culture was studied in asthmatic children with and without HS. Interleukin-2 induced an additional stimulatory effect on the lymphoproliferative response to HDM and to phytohaemagglutinin in patients who never received HS, but had no effect in patients receiving HS. We conclude that HS treatment seems to have an inhibiting effect upon this proliferative response, not only inhibiting the degree of the allergen-induced lymphocyte proliferation, but also inhibiting the sensitivity of proliferating lymphocytes for IL-2. These inhibiting effects upon lymphocytic activation could be responsible for the anti-inflammatory effects (i.e. suppression of the late asthmatic reaction) of HS.
在本研究的第一部分,我们对正常儿童(n = 16)、从未接受过脱敏治疗(HS)的哮喘儿童(n = 50)以及接受HDM脱敏治疗至少6个月的哮喘儿童(n = 20),研究了培养物中淋巴细胞对屋尘螨(HDM)刺激的增殖反应(淋巴细胞转化试验)。结果以每分钟衰变次数(d.p.m.)和刺激指数(SI = 存在变应原时的d.p.m./对照培养物中的d.p.m.)表示。在从未接受过HS的哮喘儿童中,54%的儿童SI呈阳性(> 2),接受HS的哮喘儿童中这一比例为30%,而正常儿童中无一例呈阳性。此外,在接受HS和未接受HS的哮喘患者之间,SI无统计学差异,尽管未接受HS的哮喘患者SI往往更高(中位数:2.13对1.38)(P = 0.10)。在第二系列实验中,我们研究了在有或无HS的哮喘儿童淋巴细胞培养物中添加白细胞介素-2(IL-2)的效果。白细胞介素-2对从未接受过HS的患者的淋巴细胞增殖反应有额外的刺激作用,使其对HDM和植物血凝素的反应增强,但对接受HS的患者无作用。我们得出结论,HS治疗似乎对这种增殖反应有抑制作用,不仅抑制变应原诱导的淋巴细胞增殖程度,还抑制增殖淋巴细胞对IL-2的敏感性。这些对淋巴细胞活化的抑制作用可能是HS抗炎作用(即抑制哮喘迟发反应)的原因。